



Terry Douglass, Ph.D.

Founder and Executive
Chairman of
the Board of
Directors, Provision
Healthcare, LLC

Founder and Executive Chairman of the
Board of Directors, Provision Healthcare, LLC

Chairman of Provision CARES Proton
Therapy Center, Provision Trust, Inc., Provision
Foundation, Inc.

Founder and CEO of ProNova Solutions, LLC

Founder & Executive Chairman, Provision Healthcare, LLC (2006—Present 13 years)

Knoxville, Tennessee Area

Provision Healthcare's strategic focus is to provide innovative technology and service solutions for cancer care including proton therapy and to develop, manage, and own proton centers and cancer centers in the USA and around the world. Proton therapy is a non-invasive treatment that uses protons to deliver a high dose of radiation directly to localized tumors with minimal damage to adjacent tissue.

The Provision CARES Cancer Center and Proton Therapy Center in Knoxville is the first of the Provision center developments and the model for other cancer centers and proton centers. Provision Cares Cancer Centers and Proton Therapy Centers are being developed in Franklin, Tennessee, Orlando, Florida, New Orleans, Louisiana and other locations in the USA and China.

The Provision proton centers all use the ProNova SC360 proton therapy system, which is the most advanced proton therapy system available, and was developed and is manufactured at ProNova Solutions, LLC at Pellissippi Place in Maryville, Tennessee. ProNova is a subsidiary of Provision Healthcare and was founded by Douglass and two former officers of CTI.

Founder and Chairman of the Board, CTI Molecular Imaging, Inc. (1983—2005 22 years)

Knoxville, TN

In 1983, Douglass and three colleagues, each graduates of The University of Tennessee, left EG&G Ortec and put their personal finances on the line to create Computer Technology and Imaging Inc., later renamed CTI Molecular Imaging, Inc. The entrepreneurs helped propel PET (positron emission tomography) technology from experimental use to clinical use gaining FDA approval and Medicare reimbursement through the FDA Modernization Act of 1997.

CTI further revolutionized diagnostic medicine by combining PET with CT (computer-assisted tomography) scans to create a leading-edge tool for early cancer detection and treatment management and by forming PETNet Radiopharmaceuticals, LLC to make unit dose positron compounds available around the world. In 2005, CTI and Siemens merged with Siemens acquiring 100% of the CTI shares for more than \$1 billion. Today, there are more than 3,000 PET and PET/CT scanners in the world.